162 related articles for article (PubMed ID: 34638315)
1. Profiling Cisplatin Resistance in Head and Neck Cancer: A Critical Role of the VRAC Ion Channel for Chemoresistance.
Siemer S; Fauth T; Scholz P; Al-Zamel Y; Khamis A; Gül D; Freudelsperger L; Wollenberg B; Becker S; Stauber RH; Hagemann J
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638315
[TBL] [Abstract][Full Text] [Related]
2. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
3. Targeting Cancer Chemotherapy Resistance by Precision Medicine-Driven Nanoparticle-Formulated Cisplatin.
Siemer S; Bauer TA; Scholz P; Breder C; Fenaroli F; Harms G; Dietrich D; Dietrich J; Rosenauer C; Barz M; Becker S; Strieth S; Reinhardt C; Fauth T; Hagemann J; Stauber RH
ACS Nano; 2021 Nov; 15(11):18541-18556. PubMed ID: 34739225
[TBL] [Abstract][Full Text] [Related]
4. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
5. p38 Mitogen-activated protein kinase modulates cisplatin resistance in Head and Neck Squamous Cell Carcinoma cells.
Roy S; Roy S; Anuja K; Thakur S; Akhter Y; Padhi S; Banerjee B
Arch Oral Biol; 2021 Feb; 122():104981. PubMed ID: 33302041
[TBL] [Abstract][Full Text] [Related]
6. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.
Hsu DS; Lan HY; Huang CH; Tai SK; Chang SY; Tsai TL; Chang CC; Tzeng CH; Wu KJ; Kao JY; Yang MH
Clin Cancer Res; 2010 Sep; 16(18):4561-71. PubMed ID: 20823140
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells.
Roy S; Roy S; Kar M; Chakraborty A; Kumar A; Delogu F; Asthana S; Hande MP; Banerjee B
Mutat Res Genet Toxicol Environ Mutagen; 2019 Oct; 846():503084. PubMed ID: 31585633
[TBL] [Abstract][Full Text] [Related]
8. Role of β-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma.
Roy S; Kar M; Roy S; Saha A; Padhi S; Banerjee B
Cell Oncol (Dordr); 2018 Apr; 41(2):185-200. PubMed ID: 29243047
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma.
Theile D; Ketabi-Kiyanvash N; Herold-Mende C; Dyckhoff G; Efferth T; Bertholet V; Haefeli WE; Weiss J
Head Neck; 2011 Jul; 33(7):959-68. PubMed ID: 20737486
[TBL] [Abstract][Full Text] [Related]
10. The expanding toolbox to study the LRRC8-formed volume-regulated anion channel VRAC.
Kolobkova Y; Pervaiz S; Stauber T
Curr Top Membr; 2021; 88():119-163. PubMed ID: 34862024
[TBL] [Abstract][Full Text] [Related]
11. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Roy S; Roy S; Kar M; Padhi S; Saha A; Anuja K; Banerjee B
J Oral Pathol Med; 2018 May; 47(5):492-501. PubMed ID: 29575240
[TBL] [Abstract][Full Text] [Related]
12. Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics.
Lee J; Park M; Ko Y; Kim B; Kim O; Hyun H; Kim D; Sohn H; Moon YL; Lim W
Tumour Biol; 2017 Apr; 39(4):1010428317695534. PubMed ID: 28381190
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
14. AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.
Chang WM; Chang YC; Yang YC; Lin SK; Chang PM; Hsiao M
J Exp Clin Cancer Res; 2019 Jun; 38(1):245. PubMed ID: 31182137
[TBL] [Abstract][Full Text] [Related]
15. The Vitamin D Receptor-BIM Axis Overcomes Cisplatin Resistance in Head and Neck Cancer.
Khamis A; Gül D; Wandrey M; Lu Q; Knauer SK; Reinhardt C; Strieth S; Hagemann J; Stauber RH
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291915
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kappaB.
Kato T; Duffey DC; Ondrey FG; Dong G; Chen Z; Cook JA; Mitchell JB; Van Waes C
Head Neck; 2000 Dec; 22(8):748-59. PubMed ID: 11084634
[TBL] [Abstract][Full Text] [Related]
17. Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines.
Inukai D; Nishimura K; Okamoto H; Sano R; Ueda H; Ota A; Karnan S; Hosokawa Y; Yoshikawa K; Suzuki S; Ueda R; Murotani K; Bradford CR; Ogawa T
Nagoya J Med Sci; 2020 Aug; 82(3):519-531. PubMed ID: 33132436
[TBL] [Abstract][Full Text] [Related]
18. IKK phosphorylation of NF-κB at serine 536 contributes to acquired cisplatin resistance in head and neck squamous cell cancer.
Li Z; Yang Z; Lapidus RG; Liu X; Cullen KJ; Dan HC
Am J Cancer Res; 2015; 5(10):3098-110. PubMed ID: 26693062
[TBL] [Abstract][Full Text] [Related]
19. Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo.
Köberle B; Ditz C; Kausch I; Wollenberg B; Ferris RL; Albers AE
Int J Oncol; 2010 May; 36(5):1277-84. PubMed ID: 20372803
[TBL] [Abstract][Full Text] [Related]
20. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
